Formulation and in vitro evaluation of self-microemulsifying drug delivery system containing fixed-dose combination of atorvastatin and ezetimibe

Chemical and Pharmaceutical Bulletin

Volumn 63, Issue 6, 2015, Pages 423-430

  Hwang, Kyu Mok ^a   Park, Shin Ae ^a   Kim, Ju Young ^b   Park, Chun Woong ^c   Rhee, Yun Seok ^d   Park, Eun Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b Woosuk University   (South Korea)

^c Chungbuk National University   (South Korea)

^d Gyeongsang National University   (South Korea)

Author keywords

Atorvastatin calcium; Ezetimibe; Fixed dose combination; Self microemulsifying drug delivery system; Solubilization

Indexed keywords

ACETIC ACID; ATORVASTATIN PLUS EZETIMIBE; DISTILLED WATER; OIL; SURFACTANT; ATORVASTATIN; DRUG COMBINATION; EMULSIFYING AGENT; EXCIPIENT; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; IN VITRO STUDY; MICROEMULSION; PH; PHYSICAL CHEMISTRY; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; ULTRAVIOLET SPECTROSCOPY; ZETA POTENTIAL; CHEMISTRY; DRUG COMBINATION; PHASE TRANSITION; SOLUBILITY;

ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; EMULSIFYING AGENTS; EXCIPIENTS; EZETIMIBE; PHASE TRANSITION; SOLUBILITY;

EID: 84940371117     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.c14-00814     Document Type: Article

References (38)

1. Lennernäs H., Clin. Pharmacokinet., 42, 1141-1160 (2003).
2. Ezzet F., Krishna G., Wexler D. B., Statkevich P., Kosoglou T., Batra V. K., Clin. Ther., 23, 871-885 (2001).
3. Oswald S., Haenisch S., Fricke C., Sudhop T., Remmler C., Giessmann T., Jedlitschky G., Adam U., Dazert E., Warzok R., Wacke W., Cascorbi I., Kroemer H. K., Weitschies W., Von Bergmann K., Siegmund W., Clin. Pharmacol. Ther., 79, 206-217 (2006).
4. Ballantyne C. M., Houri J., Notarbartolo A., Melani L., Lipka L. J., Suresh R., Sun S., Le Beaut A. P., Sager P. T., Veltri E. P., Ezetimibe Study Group, Circulation, 107, 2409-2415 (2003).
5. Conard S. E., Bays H. E., Leiter L. A., Bird S. R., Rubino J., Lowe R. S., Tomassini J. E., Tershakovec A. M., Am. J. Cardiol., 102, 1489-1494 (20 08).
6. Brittain G. H., Bansal K. A., Jain R., Puri V., Kohli G., Meena L. C., Kumar L., Sonje M., "Profiles of Drug Substances, Excipients, and Related Methodology", Vol. 35, ed. by Harry Brittain G., Elsevier, 2010, pp. 1-70.
7. Lestari L. A. D. M., Ardiana F., Indrayanto G., "Profiles of Drug Substances, Excipients, and Related Methodology", Vol. 36, ed. by Harry Brittain G., Elsevier, 2011, pp. 103-149.
8. Danielsson I., Lindman B., Colloids Surf., 3, 391-392 (1981).
9. Pouton C. W., Adv. Drug Deliv. Rev., 25, 47-58 (1997).
10. Neslihan Gursoy R., Benita S., Biomed. Pharmacother., 58, 173-182 (2004).
11. Bandyopadhyay S., Katare O., Singh B., Colloids Surf. B Biointerfaces, 100, 50-61 (2012).
12. Kawakami K., Yoshikawa T., Moroto Y., Kanaoka E., Takahashi K., Nishihara Y., Masuda K., J. Control. Release, 81, 65-74 (2002).
13. O'Driscoll C. M., Eur. J. Pharm. Sci., 15, 405-415 (2002).
14. Xiao H. P., Li Z. Y., Ward O. P., J. Ind. Microbiol., 14, 416-419 (1995).
15. U. S. Food and Drug Administration. "FDA-Recommended Dissolution Methods.": 〈http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm〉, cited October 17, 2014.
16. Borhade V., Nair H., Hegde D., AAPS PharmSciTech, 9, 13-21 (2008).
17. Warisnoicharoen W., Lansley A., Lawrence M., Int. J. Pharm., 198, 7-27 (2000).
18. Malcolmson C., Lawrence M. J., Colloids Surf. B Biointerfaces, 4, 97-109 (1995).
19. Ammar H. O., Salama H., Ghorab M., Mahmoud A., AAPS PharmSciTech, 10, 808-819 (2009).
20. Hugger E. D., Novak B. L., Burton P. S., Audus K. L., Borchardt R. T., J. Pharm. Sci., 91, 1991-2002 (2002).
21. Mountfield R. J., Senepin S., Schleimer M., Walter I., Bittner B., Int. J. Pharm., 211, 89-92 (2000).
22. Da Silva M. E., Meirelles N. C., Toxicol. In Vitro, 18, 859-867 (2004).
23. Gao Z., Choi H., Shin H., Park K., Lim S., Hwang K., Kim C., Int. J. Pharm., 161, 75-86 (1998).
24. Narang A. S., Delmarre D., Gao D., Int. J. Pharm., 345, 9-25 (2007).
25. Mason T. G., Wilking J., Meleson K., Chang C., Graves S., J. Phys. Condens. Matter, 18, R635-R666 (2006).
26. Lawrence M. J., Rees G. D., Adv. Drug Deliv. Rev., 45, 89-121 (2000).
27. Spernath A., Aserin A., Ziserman L., Danino D., Garti N., J. Control. Release, 119, 279-290 (2007).
28. Duc Hanh N., Mitrevej A., Sathirakul K., Peungvicha P., Sinchaipanid N., Drug Dev. Ind. Pharm., 2013, 1-11 (2013).
29. Xi J., Chang Q., Chan C. K., Meng Z. Y., Wang G. N., Sun J. B., Wang Y. T., Tong H. H., Zheng Y., A APS PharmSciTech, 10, 172-182 (20 09).
30. Uemura Y., Watarai M., Ishii H., Koyasu M., Takemoto K., Yoshikawa D., Shibata R., Matsubara T., Murohara T., J. Cardiol., 59, 50-56 (2012).
31. Illingworth D. R., Crouse J. R. 3rd, Hunninghake D. B., Davidson M. H., Escobar I. D., Stalenhoef A. F., Paragh G., Ma P. T., Liu M., Melino M. R., O'Grady L., Mercuri M., Mitchel Y. B., Curr. Med. Res. Opin., 17, 43-50 (2001).
32. Paolino D., Ventura C. A., Nistico S., Puglisi G., Fresta M., Int. J. Pharm., 244, 21-31 (2002).
33. Malcolmson C., Satra C., Kantaria S., Sidhu A., Lawrence M. J., J. Pharm. Sci., 87, 109-116 (1998).
34. Kosoglou T., Statkevich P., Johnson-Levonas A., Paolini J. F., Bergman A. J., Alton K. B., Clin. Pharmacokinet., 44, 467-494 (2005).
35. Riegelman S., Allawala N., Hrenoff M., Strait L., J. Colloid Sci., 13, 20 8-217 (19 58).
36. Li X., Yuan Q., Huang Y., Zhou Y., Liu Y., AAPS PharmSciTech, 11, 672-678 (2010).
37. Egerton R. F., Li P., Malac M., Micron, 35, 399-409 (2004).
38. Borhade V., Pathak S., Sharma S., Patravale V., Int. J. Pharm., 431, 138-148 (2012).